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PARKINSONISM: NEUROLOGICAL CONSIDERATIONS 
1. DANA DARNLEY, M.D.* 
In this discussion we shall concern ourselves with: 1. a brief review of current 
theories on the genesis and maintenance of alternating tremor and rigidity; 2. the 
clinical features of Parkinsonism with attention to early symptoms and signs; and 3. 
the medical treatment, including some comments of cflnical interest on the chemistry 
and pharmacology of anti-Parkinson drugs. Modern surgical methods of treatment 
(chemopallidolysis, etc.) will not be considered in this paper. 
A. The Pathophysiology of Parkinsonism 
Whatever the type of Parkinsonism (v. i . ) , the hallmark of the syndrome is rest 
tremor and/or rigidity; in fact, some have contended that this pervading rigidity is 
the basis of almost all other disorders of movement in Parkinsonism—to wit, the 
abnormalities of gait and posture, the diminished rate and frequency of movement, etc. 
Now, the exact neural mechanism responsible for the origin and persistence of this 
rigidity and tremor remains one of the major mysteries of this syndrome. In other 
words, we still think of Parkinsonism as a classic example of so-called basal ganglia 
disease; and rightly so, in that the pathology, at least, is concentrated primarily in the 
substantia nigra and globus pallidus, less consistently in the striatum, and even less 
conspicuously in the red nucleus, all of which are definite constitutents of the basal 
ganglia. But, though we know where lesions are common, we do not know exactly how 
these particular lesions so disturb the normally smooth functioning of interdependent 
pyramidal and extrapyramidal systems as to produce alternating tremor and rigidity, the 
two cardinal symptoms and signs. Theories, evolved from the facts of pathologic 
anatomy and physiology in humans and in experimental animals, have generally pointed 
to the tremor and rigidity as 'release' phenomena, a loss of modulation, the result of a 
break in the "chain of (motor) command", as it were. Despite general acceptance of 
this 'release' concept, however, there are differences of opinion on exactly what is 
released. For example, Bucy interprets the globus pallidus lesions as a break in the 
"chain of command" from cortical suppressor area 4S to primary motor area 4— 
in other words, he bases his theory on the presumed normal regulatory influence of 
suppressor area 4S on motor area 4 by way of the suppressor circuit running from 4S 
to caudate nucleus, then to the globus pallidus, then to the thalamus (ventro-lateral 
nucleus), then back to area 4; thus when the globus pallidus link is damaged as in 
Parkinsonism, the suppressor circuit chain is broken, and tremor (and rigidity) result 
from the unsuppressed pyramidal outflow from area 4. On the other hand, Jenkner 
and Ward' and Falkerts and Spiegel' on the basis of experimental work on animals (both 
stimulation and destruction experiments on the reticular formation in the mid-brain 
tegmentum) feel that the globus pallidus (and substantia nigra) lesions release other 
normally subservient nuclear groups in the brain stem reticular formation from pallidal 
and nigral control, giving free rein to these other nuclear groups which give rise to 
the reticulo-spinal tract, the extrapyramidal system's major 'voice' in influencing lower 
motor neurone activity at all spinal levels. Thus, Bucy sees all this as a break in 
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suppressor circuit influence on pyramidal outflow while other investigators see it as 
a break in paflidal and nigral control of downstream (reticulospinal) extrapyramidal 
outflow. In this setting of conflicting views and unproven theories, the basic patho-
physiology is still to be explained. 
The most recent ray of hope for better understanding of this tremor-rigidity 
problem is the work of Granit' who points out that not only the upper motor neurone 
(both pyramidal and extra pyramidal components) but also the lower motor neurone 
plays an important role in regulating muscle tone. This lower motor neurone mechanism, 
the so-cafled gamma loop, is a "feed-back" or "servo-system", originating in the small 
gamma anterior hom cefls which innervate the muscle spindle fibers; innervated, these 
fibers contract and, by stretching the sense organ in the spindle, set up afferent stimuli 
to the large alpha anterior hom cells which innervate the started muscles and hence 
directly influence their tone and movement, disorders of which characterize Parkin-
sonism. Thus, from Granit's work it is clear that the alpha anterior horn cells can be 
driven indirectly through the gamma loop to the spindles as well as directly by other 
pathways covering upon the alphas. This all ties in, in theory at least, with the 
role of the central neural mechanisms described above in that the gamma system 
appears to be activated particularly by the brain stem reticular formation (extra-
pyramidal) and the alpha cells to be activated by the pyramidal tract. At this time, it 
is fair to say that this very recent addition to our knowledge of the control of move-
ment is still too young to have borne definite clinical 'fruit'. 
B. The Cflnical Features of Parkinsonism 
Whereas the inner workings of this syndrome remain an enigma, the outer trappings 
of the advanced stage, at least, are familiar to everyone. The combination of rest 
tremor, rigidity, poverty and inertia of movement, the loss of associated and ex-
pressional movements of arms and face; the masked facies and monotonous speech; 
the drooling; the shuffling or festinating gait—this is, unmistakably, advanced Parkin-
sonism. There is no problem in diagnosis here except in our attempt to categorize 
further as: idiopathic, post-encephalitic, or arteriosclerotic. Despite arguments to the 
contrary, in practice this can be difficult. With a history of encephalitis, of insidious 
onset of rigidity first and foremost, of oculo-gyric crises, of drowsiness, and of deficits 
in convergence and accommodation, a diagnosis of post-encephalitic type is justified; 
but, in my experience this is not a common happenstance. If , on the other hand, the 
patient is in the fifth or sixth decade and notices rather sudden onset of the characteristic 
tremor, followed by the other signs described previously, then a diagnosis of idiopathic 
type would be reasonable; this, by the way, is the type that Parkinson described in his 
1817 Essay On The Shaking Palsy (or Paralysis Agitans). Finally, if the patient is in 
his seventh or eighth decade, is coincidentally hypertensive with mfld to moderate 
dementia and possibly some pseudobulbar symptoms, and develops rigidity insidiously, 
then the arteriosclerotic type is probable. 
The early Parkinsonism of insidious onset can be missed, especially in patients 
in the third to fifth decades, unless we pay particular attention to their complaints of 
stiffness or heaviness of the arms and legs, weakness or slowness, fatigability and muscle 
cramps or, even more obscurely, "deadness or numbness" of the arms and legs. In the 
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setting of these complaints, we must recognize the significance of our findings of reduced 
frequency of lid-blinking, failure of one or both arms to swing automatically when 
the patient walks, rigidity in the proximal joints (shoulder and hip), difficulty with 
the rapid rhythmic alternating movements of fingers and hands, the tendency for hand-
writing to get smafler and smaller the longer the patient writes at one sitting. There is 
also a so-called "spiked knuckles" sign, indicating the relative prominence of the 
metacarpophalangeal joints due to the dominance of finger flexor tendon tone over 
extensor tendon tone in early Parkinsonism. It is also important to recognize that uni-
lateral involvement of the face, arm, and leg in these early cases is common and 
constflutes the so-called hemi-Parkinsonism. Even in these early cases, the slowness 
or inertia in the beginnings and endings of movements may be brought out and easily 
seen when the patient attempts a 90 degree or, particularly, a 180 degree turn while 
walking; in so doing, the rate of leg movement is conspicuously slowed and the rhythm 
disturbed until straight-line walking is again attained. 
In the differential diagnosis, rarely an intracranial tumor, primary or metastatic, 
in the neighborhood of the basal ganglia may mimic the clinical picture described, 
particularly the hemi-Parkinsonism. 
C. The Medical Treatment of Parkinsonism 
The total care of these patients has three major aspects—1. pharmaceutical; 2. 
physiotherapeutic; 3. psychiatric. For the most part those of us in office practice lean 
heavily on the first of these and take care of the second and third needs by urging 
and helping the patient to seek new channels of expression, at both physical and verbal 
levels, during every visit to our office. The special skills of physiatrist or psychiatrist 
may and should be sought when indicated, of course. Physiotherapy, for example, has 
something to offer in posture-correction, gait-training, muscle-stretching, progressive 
resistive exercises, and occupational therapy. 
The treatment of Parkinsonism is symptomatic, of course, since the underlying 
neural mechanisms are stifl not understood. The major symptoms treated are, of 
course, tremor and rigidity with all their by-products. 
There is an already abundant but ever-increasing supply of pharmaceuticals of 
value in treating Parkinsonism, but they afl come under the heading of four main 
drug groups—namely, potato plant products and derivatives (the solanaceous alka-
loids) ; the synthetic antispasmodics; the synthetic anti-histaminics; the synthetic cerebral 
stimulants. The potato plant products which include Atropine, Hyoscine, Hyoscyamine, 
Stramonium, Belladonna, and Rabellon are the time-honored medicaments for Parkin-
sonism (Charcot refers to the use of Befladonna and Hyoscyamine in his 1877 text 
on diseases of the nervous sytem); these are stifl of definite value. In about the last 
15 years the synthetic products mentioned above have become avaflable. The best of 
the anti-spasmodics have included Artane, Pagitane, and Cogentin. The antihistaminics in 
common use have included Benadryl and Thephorin and the synthetic cerebral stimu-
lants (Dexedrine and Benzedrine) have found some use in the snecific treatment of the 
lethargy and akinesia of Parkinsonism. 
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Structural formulas of some anti-Parkinson drugs; note similarities (see text). 
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A few general rules should be remembered in the use of these agents: 1. Caution 
in dosage with any of these drugs in the older patients; heavy dosage may lead to ex-
cessive drowsiness or excitement, confusion or hallucinations, gastrointestinal disturb-
ances. 2. Each drug deserves use up to tolerance before switching to another. 3. Com-
binations of drugs may be best—as for example, giving Artane for rigidity and central 
stimulation along with Hyoscine or Benadryl for tremor. 4. Atropine is a suitable choice 
for rigidity in the young, but is never to be used in the old because of the threat of 
glaucoma. 5. The most frequent side effects to be watched for in the use of many of 
these drugs—dryness of the mouth and blurring of vision. 6. In general, post-en-
cephalitic types have tremendous tolerance for any drugs, arteriosclerotic types have least 
tolerance. 7. Artane or Pagitane are usually good drugs with which to start and, in 
general, are safe enough for any age group. 8. Spectacular initial response is not too 
unusual, but probably will "wear off" in time. This same response, though usually 
less spectacular, may be repeated on shifting to other drugs. 9. Hence, rotation of 
drugs is to be borne in mind in the care of these chronic patients. 10. Some of these 
drugs seem to have rather selective action—for example, for rigidity. Atropine, Artane, 
or Cogentin seem best; for tremor, Hyoscine, Benadryl, or Stramonium; for akinesia, 
Dexedrine or Artane; for oculogyria, Artane, Pagitane, or Atropine. 
It is interesting to note that the "old" potato plant products and the "new" syn-
thetics (both anti-spasmodics and anti-histaminics) bear some definite similarities in 
chemical structure (see structural formulas illustrated); hence their fairly similar 
effectiveness in Parkinsonism should come as no great surprise. Trasentine, developed 
during the 1930's in a search for a synthetic Atropine-like drug, was itself ineffectual 
in Parkinsonism but became the prototype of Artane and other effective synthetic 
anti-spasmodics. Interestingly, though, this same Trasentine which sparked the develop-
ment of all the synthetic anti-spasmodics bears an even stronger chemical structural 
resemblance to Benadryl, the anti-histaminic (q.v.), than it does to Artane! This 
trend of chemical similarities in effective anti-Parkinson drugs is epitomized by Cogentin 
in that it combines the "virtues"—in this case, the active radicles—of Atropine (peer 
of the old potato plant products) and Benadryl (the anti-histaminic). 
In connection with Cogentin, Himwich and Rinaldi^ and other collaborators have 
done some interesting work lately in determining the site of action of this and related 
drugs. In studies on rabbits, they have found that Cogentin and other effective anti-
Parkinson drugs seem to work at the level of the reticular system (a cholinergic system), 
by their anti-cholinergic action reducing or eliminating both the upstream as well as 
downstream effects of the activating system. Himwich points to this as a possible explan-
ation for both the subjective and objective improvement in Parkinsonism patients on 
these drugs—in effect, a pharmacological lobotomy (diminishing the upstream arousal 
stimuli from the brain stem reticular formation) and a pharmacological tractotomy of 
the reticulo-spinal tracts (diminishing the downstream effect of theoretically 'released' 
extrapyramidal efferents). In this last, Himwich's theory clearly embraces the ideas 
of Jenkner and Ward and Falkerts and Spiegel described above. From this experience, 
Himwich has further suggested using the reticular activating system in this way for 
screening anti-Parkinson drugs developed in the future. 
This has been a glimpse of Parkinsonism in 1958, one hundred and forty-one 
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years after James Parkinson wrote, with undaunted optimism and with words that 
stfll apply, "but, although, at present, uninformed as to the precise nature of the 
disease, still it ought not to be considered as one against which there exists no counter-
vailing remedy" and then added, in saluting future investigators, "by their benevolent 
labours, its real nature may be ascertained and appropriate modes of relief, or even 
of cure, pointed out". 
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